/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present data from the ARTISTRY-1 clinical trial for nemvaleukin alfa (nemvaleukin), the...
Related Keywords
United States , Texas , Massachusetts , Athlone , Westmeath , Ireland , Waltham , Ohio , Dublin , Michigan , Cincinnati , Kenilworth , Chicago , Illinois , American , Sarinaa Piha Paul , Thomasj Herzog , Craig Hopkinson , Jill Odonnell Tormey , Jeffreys Weber , Los Angeles , Omid Hamid , Ulkan Vaishampayan , Sandy Coombs , Sourojit Bhowmick , Division Of Cancer Medicine , American Society Of Clinical Oncology , Isaac Perlmutter Cancer Center , Cancer Research Institute , Research Development At Alkermes , Research Development , Nasdaq , University Of Michigan , Merck Co Inc , York University School Of Medicine , Department Of Investigational Cancer Therapeutics , Translational Research , Alkermes , Phasei Program , University Of Cincinnati Cancer Institute , University Of Texas Md Anderson Cancer Center , Clinical Development Program , Merck Sharp Dohme Corp , Exchange Commission , Division Of Hematology Oncology , Research Institute , Company To Host Investor Webcast On , Scientific Affairs , Showed Anti Tumor Activity , Multiple Tumor Types , Host Investor Webcast , Clinical Oncology , Annual Meeting , Internal Medicine , Chief Medical Officer , Executive Vice President , Combination With Pembrolizumab , Jillo Donnell Tormey , Chief Executive Officer , Cancer Research , Deputy Director , Cincinnati Cancer Institute , Associate Director , Associate Professor , Investigational Cancer Therapeutics , Cancer Medicine , New York University School , Cutaneous Oncology , Melanoma Therapeutics , Phasei Immuno Oncology Program , Angeles Clinic , Cedars Sinai Affiliate , Deputy Director University , Nemvaleukin Alfa , Private Securities Litigation Reform Act , Annual Report , Merck Sharp , Dohme Corp , Alkermes Plc ,
comparemela.com © 2020. All Rights Reserved.